Last reviewed · How we verify
Proellex Formulation B
At a glance
| Generic name | Proellex Formulation B |
|---|---|
| Also known as | telepristone acetate |
| Sponsor | Repros Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Proellex® Pharmacokinetic Bridging Study II (PHASE1)
- Comparison of Two Formulations of Proellex for Oral Administration (PHASE1)
- Comparison of Two Formulations of Proellex for Vaginal Administration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Proellex Formulation B CI brief — competitive landscape report
- Proellex Formulation B updates RSS · CI watch RSS
- Repros Therapeutics Inc. portfolio CI